Jan 7 (Reuters) - Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback